Targeted Stress Modulation in S.aureus to Combat Resistant Infections via Bioactive Hybrid Therapy

Overview

1 out of 4 patients die within 3 months of a bloodstream infection from Staphylococcus aureus (S.aureus) [1]. Currently, both first-line and even last-resort antibiotics are mainly ineffective against infections by S.aureus because of its resistant mechanisms and stress response pathways that enhance bloodstream survival. To address this, I developed a bioactive hybrid treatment which targets multiple stress pathways in contrast to just one, compared with current treatment options. My treatment combines an Antimicrobial Peptide(AMP): DJK-5, with specific compounds derived from discarded Humulus lupulus(Hop) plants. Aiming to not only disrupt and eradicate the infection, but also to minimize the unwanted side effects current drugs inflict on patients, in order to break the toxic cycle of bacterial resistance. While this research is a work-in-progress towards clinical applications, this combination treatment has the potential to improve the long-term outcomes and quality of life for patients battling resistant infections.

Awards (4)

• Young Scientist Award
• Special Award
• Gold Medal
• Selected for CWSF 2026

Competition history

• CWSF 2026 Disease & Illness

Related projects

Closest projects by meaning, across every fair and year in the corpus.